Skip to content

Follow-up Study on the Safety and Efficacy of Endovascular Treatment for Acute Basilar Artery Occlusion

Follow-up Study on the Safety and Efficacy of Endovascular Treatment for Acute Basilar Artery Occlusion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082236
Enrollment
Unknown
Registered
2024-03-25
Start date
2024-03-28
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basilar Artery Occlusion

Interventions

Endovascular thrombectomy combined with drug treatment group:None

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1) Symptoms and signs compatible with ischemia in the basilar artery territory; 2) Basilar artery occlusion confirmed by computed tomographic angiography (CTA)/ magnetic resonance angiography (MRA)/ digital substraction angiography (DSA); 3) Age of 18 years or older; 4) Time from stroke onset to randomization within 12 hours of estimated time of basilar artery occlusion; 5) The patient or their legal representative signs an informed consent form; 6) National Institutes of Health Stroke Scale (NIHSS) score =10 at the time of neuroimaging.

Exclusion criteria

Exclusion criteria: 1) Premorbid mRS =3 for patients185 mmHg or diastolic pressure >110 mmHg, and cannot be controlled by antihypertensive drugs; 7) Known genetic or acquired bleeding diathesis, lack of anticoagulant factors, or oral anticoagulant drugs and INR > 1.7; 8) Blood glucose 22.2 mmol / L; platelet count < 50×10^9 / L, or hematocrit < 25%; 9) Life expectancy < 1 year; 10) Patients that cannot complete 90-day follow-up (e.g. no fixed residence, overseas patients, etc.); 11) The patient develops acute ischemic cerebral infarction within 48 hours after percutaneous coronary or cerebrovascular intervention surgery or major surgery (if it exceeds 48 hours, the patient can be enrolled); 12) Premorbid cerebrovascular inflammation; 13) Premorbid nervous system disease or mental disorders hindering the assessment of 3-month functional outcomes. Imaging exclusion criteria 14) CT/MR shows intracranial hemorrhage (patients with microbleeds on MR can be included if lesion diameter =5mm); 15) CTA/MRA/DSA shows the vascular anatomy is severely tortuous, has an anatomic variation, or is severely stenotic or dissected that would preclude the navigation of the thrombectomy devices to the target vessel; 16) PC-ASPECTS on CT/CTA-Source Images/MRI-DWI <6 for patients <80 years (<8 for patients =80 years); 17) CT or MR shows the cerebellar infarction with obvious space occupying effect and obvious compression of the fourth ventricle; 18) Complete bilateral thalami or bilateral brainstem infarction confirmed by CT/MR; 19) Simultaneous occlusion of both anterior and posterior circulation confirmed by CTA/MRA/DSA; 20) Intracranial tumors (except small meningiomas).

Design outcomes

Primary

MeasureTime frame
modified Rankin scale ;

Secondary

MeasureTime frame
EQ-5D-5L Score;Barthel index;All-Cause Mortality;

Countries

China

Contacts

Public ContactWei Hu

The First Affiliated Hospital of University of Science and Technology of China

andinghu@ustc.edu.cn+86 151 5551 0611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026